Cover Image

Results from the grant "Adoptive nanotherapy against ATF4 in triple negative breast cancer patients-derived models"

Fuente: Zenodo

Saved in:

Bibliographic Details
Main Authors:	Sergio Granados-Principal, Cara, Francisca, Calahorra, Jesús, Blaya-Cánovas, Jose L., López-Tejada, Araceli, González González, Adrián, GRIÑAN, CARMEN
Format:	Recurso digital
Published:	Zenodo 2025
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Multipathway regulation induced by 4‐(phenylsulfonyl)morpholine derivatives against triple‐negative breast cancer
by: Fan‐Wei Yang, et al.
Published: (2024)

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
by: Hyun Cheol Chung, et al.
Published: (2024)

Radiological diagnostics of triple negative breast cancer: a review
by: Sigutė Stadalnykaitė
Published: (2011)

Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancers.
by: Cogoluegnes, Sarah, et al.
Published: (2026)

Xist is activated during resistance in triple negative breast cancer in vitro.
by: Mamoor, Shahan
Published: (2025)

Multi‐omic analysis of dysregulated pathways in triple negative breast cancer
by: Fatima Sajjad, et al.
Published: (2024)

Guideline concordance in triple‐negative breast cancer: What does it measure?
by: Jennifer L. Caswell‐Jin, et al.
Published: (2026)

Combined use of immunoreactivities of Efp and ZCCHC3 for predicting prognosis of patients with triple‐negative breast cancer
by: Akihiro Fujimoto, et al.
Published: (2025)

Therapeutic targeting in androgen receptor-negative triple negative breast cancer (AR- TNBC): HUNK.
by: Mamoor, Shahan
Published: (2025)

Reconciliación metodológica e intercultural: posibilidades de la enseñanza comunicativa de lenguas en China
by: ALBERTO SÁNCHEZ GRIÑÁN
Published: (2009)

PTGER3 knockdown inhibits the vulnerability of triple‐negative breast cancer to ferroptosis
by: Song Wang, et al.
Published: (2024)

Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancer
by: Yuechen Wang, et al.
Published: (2024)

Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients
by: Chiara Massa, et al.
Published: (2024)

Electroporation-mediated Metformin for effective anticancer treatment of triple-negative breast cancer cells
by: Sahu, Praveen, et al.
Published: (2024)

Genomic and transcriptomic profiling of pre‐ and postneoadjuvant chemotherapy triple negative breast cancer tumors
by: Tomomi Nishimura, et al.
Published: (2024)

Correction to “The SWI/SNF ATPases are required for triple negative breast cancer cell proliferation”
Published: (2024)

A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer
by: Kathy D. Miller, et al.
Published: (2026)

MW‐19, a dihydropyrazole derivative, induces human triple‐negative breast cancer cell apoptosis by targeting apoptosis‐related pathways
by: Nanting Zou, et al.
Published: (2024)

Therapeutic targeting in androgen receptor-positive triple negative breast cancer (AR+ TNBC): THTPA.
by: Mamoor, Shahan
Published: (2025)

Therapeutic targeting in androgen receptor positive triple negative breast cancer (AR+ TNBC): FGR.
by: Mamoor, Shahan
Published: (2025)

HDAC inhibitor regulates the tumor immune microenvironment via pyroptosis in triple negative breast cancer
by: Xue Yang, et al.
Published: (2024)

SBFI26 induces triple‐negative breast cancer cells ferroptosis via lipid peroxidation
by: Gang He, et al.
Published: (2024)

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer
by: Nur Aininie Yusoh, et al.
Published: (2025)

Adding carboplatin to adjuvant chemotherapy improved survival in early‐stage triple‐negative breast cancer
by: Leah Lawrence
Published: (2026)

Extracellular matrix cancer‐associated fibroblasts promote stromal fibrosis and immune exclusion in triple‐negative breast cancer
by: Xunxi Lu, et al.
Published: (2025)

Therapeutic targeting in androgen receptor positive triple negative breast cancer (AR+ TNBC): PINK1.
by: Mamoor, Shahan
Published: (2025)

Therapeutic targeting in androgen receptor positive triple negative breast cancer (AR+ TNBC): GRK3.
by: Mamoor, Shahan
Published: (2025)

SAA1‐dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness
by: Ilona Rybinska, et al.
Published: (2024)

89Zr‐Labeled DFO@Durvalumab‐HSA nanoparticles: In vitro potential for triple‐negative breast cancer
by: Fatma Yurt, et al.
Published: (2024)

Tristetraprolin affects invasion‐associated genes expression and cell motility in triple‐negative breast cancer model
by: Anastasiia Hubiernatorova, et al.
Published: (2024)

Ezetimibe inhibits the migration and invasion of triple‐negative breast cancer cells by targeting TGFβ2 and EMT
by: Lingkai Kong, et al.
Published: (2024)

Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer
by: Xiaojie Liang, et al.
Published: (2025)

Siglec15/ TGF ‐β bispecific antibody mediates synergistic anti‐tumor response against 4T1 triple negative breast cancer in mice
by: Limei Shen, et al.
Published: (2024)

Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights
by: Dalia S. El‐Gamil, et al.
Published: (2024)

Implication of IZUMO2 in the cell‐in‐cell phenomenon: A potential therapeutic target for triple‐negative breast cancer
by: Toshiya Higashi, et al.
Published: (2024)

Lnc00113 promotes triple‐negative breast cancer progression via the NOB‐1/MAPK signaling axis
by: Xiaoyu Li, et al.
Published: (2024)

Exploration of the sensitization effect of Chaihu Shugan powder on chemotherapy for triple‐negative breast cancer and its active ingredients
by: Wei Wei, et al.
Published: (2024)

Intraline genomic heterogeneity of the triple-negative breast cancer MDA-MB-231-luc-GFP cell line.
by: Varela-Rouco, Nair, et al.
Published: (2025)

Activation of the γ-secretase/NICD-PXR/Notch pathway induces Taxol resistance in triple-negative breast cancer.
by: Wang, Zuo-Jun, et al.
Published: (2024)

LOXL 2‐mediated chromatin compaction is required to maintain the oncogenic properties of triple‐negative breast cancer cells
by: Gemma Serra‐Bardenys, et al.
Published: (2024)